12 Emerging Companies to Watch in Neurotech Space

Brain-computer interface (BCI) technologies are rapidly becoming the spotlight of the neurotech industry, with Neuralink at the forefront. Recently, Neuralink implanted its first brain chip in a human, marking a significant milestone in human-computer interaction. This implant allows users to control devices with their thoughts, with potential future applications in curing blindness and neuron damage​. In July 2025. Neuralink also started its first UK trial of the N1 brain implant, designed to let people with paralysis control digital devices using brain signals, at hospitals in London and Newcastle.

A close rival, Synchron, has just announced an innovative use of its BCI system, enabling a patient with ALS to control the Apple Vision Pro using only brain signals. This breakthrough allows for hands-free and voice-free interaction, enhancing accessibility for those with severe motor impairments. The Synchron BCI, implanted through a minimally invasive procedure, detects and transmits motor intent from the brain to control digital interfaces​ (Med Xpress)​.

But here, I decided to summarize some lesser-known emerging players in the neurotech space, which are developing intriguing technologies worth keeping an eye on.

#advertisement

Arctop

Founded by Dan Furman and Eitan Kay in Los Angeles, California, Arctop develops software that uses artificial intelligence to analyze brain activity. Arctop's tools aim to translate feelings, reactions, and intent, optimizing skill training and enabling new forms of communication.

The company raised $10M in series A funding.

Diagnostic Biochips

US-based Diagnostic Biochips, founded by Dr. Brian Jamieson, a former NASA engineer is empowering neuroscientists to conduct advanced electrophysiology research aimed at curing complex neurological diseases such as Parkinson’s and epilepsy. Recently, the company has announced SomaFocus for intact organoid recording; a September 2025 preprint using it showed automated high-density recordings and classification of healthy vs. familial Alzheimer’s organoids. 

Utilizing patented technologies, including a microfabricated implantable neurosensor and data analysis software, the company provides high-fidelity brain data with exceptional spatiotemporal resolution. Diagnostic Biochips recently received a $500,000 commercialization award from the MSCRF to advance the platform. 

The company states to have received $6 million in R&D funding from the NIH and DARPA.

Neurable

Based in Boston and founded by Ramses Alcaide, Neurable aims to eliminate limitations by creating technology that enables control of computers using brain signals. Their brain-computer interface allows users to interact with software and devices solely through brain activity. After the MW75 Neuro launch in 2024—a noninvasive EEG BCI embedded in consumer headphones via Master & Dynamic—Neurable introduced the MW75 Neuro LT as a follow-up to the previous model. 

The company has raised $13M in its latest funding round.

Ceribell

Ceribell, led by founders Chris Chafe, Xingjuan (Jane) Chao, and Josef Parvizi, has developed the first AI-powered point-of-care EEG diagnostic system, embedding their proprietary machine learning algorithm Clarity. This system aims to revolutionize seizure management in acute care by making EEG diagnostics more accessible, efficient, and cost-effective. FDA recently expanded Clarity to pediatric patients ≥1 year, which the company says makes it the first and only FDA-cleared AI for electrographic seizure detection across ages 1+. The system also obtained FedRAMP High authorization for U.S. federal deployments.

Latest funding — $207M from IPO.

Neuromod Devices

Dublin company Neuromod Devices, founded by Ross O'Neill, focuses on developing bi-modal neuromodulation devices to treat tinnitus, a condition characterized by ringing in the ears.

Their flagship product, Lenire, is designed to significantly reduce the suffering of patients with chronic and debilitating conditions. Nature Communications Medicine published real-world U.S. data reporting 91.5% with clinically meaningful improvement after ~12 weeks using Lenire. 

The company has recently closed a €10M equity round to scale U.S. and EU rollout, as well as achieved MDSAP and EU MDR certifications to support broader market access.

Paradromics Inc.

Founded in 2015 by Andreas Schaefer and Matt Angle, Texan company Paradromics is developing a brain-computer interface (BCI) to aid individuals with severe neurological conditions. This technology focuses on enabling communication for motor-impaired individuals.

The company has recently completed a first-in-human recording at the University of Michigan using its Connexus BCI, which records single-neuron activity and uses AI to translate brain signals into outputs.

The company has received support from NIH, DARPA, and venture capital, raising $33 million in Series A funding, as well as an undisclosed strategic investment from NEOM Investment Fund.

BrainCheck

Another Texan company, BrainCheck, founded by neuroscientists including David Eagleman and Yael Katz, offers digital tools for cognitive health. Their platform enables screening, detection of cognitive decline, and care planning. Recently, UPMC began rolling out BrainCheck in primary care. It was also selected for the pan-European PREDICTOM study.

The company has secured $15 million in funding and integrates its tools into EHR systems for healthcare providers.

Omind Neurotechnologies

Based in Paris, France, Omind Neurotechnologies, founded by Jonas Chatel-Goldman, Deborah Varoqui, Guillaume Victor-Thomas, and Nicolas Bassan, develops brain training tools to enhance mental performance and treat mental health issues. With extensive R&D and collaborations with IRBA, CNRS, and AP-HP, they offer personalized and effective training solutions.

Earable Neuroscience

Earable Neuroscience, based in Boulder, Colorado, is led by founder Tam Vu. The company uses advanced neuroscience to improve daily life, focusing on sleep. Their FRENZ Brainband tracks and stimulates brain activity in real time using bone-conduction speakers.

The company is supported by FoundersFund, SmileGate, 500, and Samsung Ventures, and has won CES Innovation and Red Dot Design Awards in 2023. The company has recently launched the Focus Flow neurofeedback app and secured a third consecutive CES Innovation Award, as well as announced Brainwaves Labs, a B2B/research platform. 

Neuspera Medical Inc.

Neuspera Medical, Inc., based in San Jose, California, and founded by Alexander Yeh, develops implantable devices to treat chronic illnesses, including urinary urgency incontinence (UUI) and chronic pain. These invasive implants, paired with external wearable transmitters, target hard-to-access anatomical locations.

Their ultra-miniaturized integrated sacral neuromodulation (iSNM) implant with an external transmitter for overactive bladder symptoms recently received FDA approval for treating urinary urge incontinence. 

The company has raised $23 million in Series D funding.

Neuronic

Neuronic focuses on enhancing brain capacity through devices that emit near-infrared light, positively impacting memory, movement, and mood stability. Neuronic has recently launched the Neuronic LIGHT, a battery-powered transcranial photobiomodulation (tPBM) helmet that delivers 1070 nm near-infrared light to the brain, combining app connectivity with large-scale real-world data collection through user participation.

The company, dedicated to advancing photobiomodulation science, invests all profits into ongoing basic science and clinical trials. They aim to develop smart medtech devices that enhance brain function throughout life.

Axoft

Axoft, founded 2021 in Cambridge, Massachusetts, develops ultrasoft intracortical implants built on Fleuron, a gold–polymer composite reported to be ~10,000× softer than standard polyimide. The tissue-matched leads are designed to bend with the brain to mitigate scarring, signal drift, and lead migration. The system pairs on-device electronics with custom tools and software and can scale to over a thousand recording points.

In 2025, the FINESSE first-in-human intraoperative study placed 128-channel Fleuron probes ~1 cm deep in four tumor-resection patients. 

Axoft is preparing a second clinical study with higher-bandwidth devices aimed at longer-term neurodiagnostics and therapeutic use. Axofot has raised $18.1M to date.

To explore the field of brain-computer interfaces in more detail, see our recent deep dive on emerging BCI technologies.

Topic: NeuroTech